In this study, we report for the first time about the positive antitumor effect of haprolid, a novel natural polyketide–peptide hybrid, in HCC models, both in vitro and in vivo through dual inhibition of Rb/E2F and Akt/mTOR pathways. The gene discussed is RB1; the disease is hepatocellular carcinoma.